Anti-PD-1/CTLA-4 Antibody
1 clinical trials · Condition
◉ Watch Anti-PD-1/CTLA-4 Antibody
| Record | Firm | Date |
|---|---|---|
| Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC (NCT07447570) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-10-15 |
Track Anti-PD-1/CTLA-4 Antibody automatically
Every clearance here is in the API, with alerts when new ones post.